160 related articles for article (PubMed ID: 20660540)
41. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
42. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
MacGregor EA; Pawsey SP; Campbell JC; Hu X
Gend Med; 2010 Apr; 7(2):88-108. PubMed ID: 20435272
[TBL] [Abstract][Full Text] [Related]
43. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials.
Dodick DW
Headache; 2002 Jan; 42(1):21-7. PubMed ID: 12005271
[TBL] [Abstract][Full Text] [Related]
44. Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
Marcus DA; Bernstein CD; Sullivan EA; Rudy TE
Headache; 2010 Apr; 50(4):551-62. PubMed ID: 20236337
[TBL] [Abstract][Full Text] [Related]
45. Oral almotriptan in the treatment of migraine: safety and tolerability.
Dodick DW
Headache; 2001 May; 41(5):449-55. PubMed ID: 11380642
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Wade A; Pawsey S; Whale H; Boyce M; Warrington S
Clin Drug Investig; 2009; 29(5):325-37. PubMed ID: 19366274
[TBL] [Abstract][Full Text] [Related]
47. Tolerability and efficacy of almotriptan in the long-term treatment of migraine.
Pascual J; Falk R; Docekal R; Prusinski A; Jelencsik J; Cabarrocas X; Segarra X; Luria X; Ferrer P
Eur Neurol; 2001; 45(4):206-13. PubMed ID: 11385257
[TBL] [Abstract][Full Text] [Related]
48. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Nett R; Mannix LK; Mueller L; Rodgers A; Hustad CM; Skobieranda F; Ramsey KE
Headache; 2008 Sep; 48(8):1194-201. PubMed ID: 18422606
[TBL] [Abstract][Full Text] [Related]
49. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
50. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
[TBL] [Abstract][Full Text] [Related]
51. A review of the clinical efficacy and tolerability of almotriptan in acute migraine.
Dodick DW
Expert Opin Pharmacother; 2003 Jul; 4(7):1157-63. PubMed ID: 12831340
[TBL] [Abstract][Full Text] [Related]
52. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
Spierings EL; Gomez-Mancilla B; Grosz DE; Rowland CR; Whaley FS; Jirgens KJ
Arch Neurol; 2001 Jun; 58(6):944-50. PubMed ID: 11405809
[TBL] [Abstract][Full Text] [Related]
53. Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine.
Mathew NT
Clin Ther; 2002 Apr; 24(4):520-9. PubMed ID: 12017397
[TBL] [Abstract][Full Text] [Related]
54. Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents.
Berenson F; Vasconcellos E; Pakalnis A; Mao L; Biondi DM; Armstrong RB
Headache; 2010 May; 50(5):795-807. PubMed ID: 20546320
[TBL] [Abstract][Full Text] [Related]
55. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
56. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.
Winner P; Lewis D; Visser WH; Jiang K; Ahrens S; Evans JK;
Headache; 2002 Jan; 42(1):49-55. PubMed ID: 12005275
[TBL] [Abstract][Full Text] [Related]
57. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Silberstein SD; Elkind AH; Schreiber C; Keywood C
Neurology; 2004 Jul; 63(2):261-9. PubMed ID: 15277618
[TBL] [Abstract][Full Text] [Related]
58. Almotriptan: a review of 10 years' clinical experience.
Pascual J; Vila C; McGown CC
Expert Rev Neurother; 2010 Oct; 10(10):1505-17. PubMed ID: 20945537
[TBL] [Abstract][Full Text] [Related]
59. Drugs for the acute treatment of migraine in children and adolescents.
Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010
[TBL] [Abstract][Full Text] [Related]
60. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
Diener HC
Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
